Keen to turn a new page, In­di­v­ior branch­es out, pick­ing up an op­tion for cannabis ad­dic­tion drug

Hav­ing put the scan­dal around its flag­ship opi­oid ad­dic­tion drug be­hind it, In­di­v­ior is branch­ing out the sub­stance abuse port­fo­lio.

The lat­est ad­di­tion comes in the area of cannabis-re­lat­ed dis­or­ders, as In­di­v­ior buys an op­tion to li­cense a CB1 in­hibitor from France’s Aelis Far­ma for the treat­ment of dis­eases like cannabis ad­dic­tion and cannabis-in­duced psy­chosis. They’re putting down $30 mil­lion in cash and promis­ing a $100 mil­lion li­cense fee pay­ment should they de­cide to ex­er­cise the op­tion af­ter see­ing Phase IIb da­ta.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER